Research Tracker›Biomarker Atlas›Atrial Fibrillation›Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP)

Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP) in Atrial Fibrillation

Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP) belongs to the other group of Atrial Fibrillation markers and is reported to be raised relative to patients in sinus rhythm (SR). The source does not tie this marker to a specific symptom cluster, so it is best read as a biological signal rather than a symptom predictor. The evidence summarised here comes from Sramko et al. 2019 and reflects averages across cohorts rather than any single patient's result.

↑ ElevatedOther

Summary

Direction in Atrial Fibrillation↑ Elevated — higher than in the comparison group
CategoryOther
Compared againstpatients in sinus rhythm (SR)
SourceSramko et al. 2019 — doi:10.1007/s00392-018-1332-1
Condition atlasAtrial Fibrillation Biomarker Atlas

Related Other markers in Atrial Fibrillation

Full list: Atrial Fibrillation Biomarker Atlas.

Frequently asked questions

Is Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP) high or low in Atrial Fibrillation?

Elevated. Studies summarised in the OSMF atlas report higher Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP) in Atrial Fibrillation than in patients in sinus rhythm (SR). Source: Sramko et al. 2019.

Which test measures Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP)?

The atlas record does not list a standardised clinical test code (LOINC) for Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP), which usually means it was measured with research assays or study-specific protocols rather than a routine clinical panel. Check the cited source for the exact method.

Is one abnormal Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP) result diagnostic of Atrial Fibrillation?

No. No single biomarker is diagnostic of Atrial Fibrillation. Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP) in Atrial Fibrillation: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 8, 2026, from https://research.opensourcemed.info/biomarkers/atrial-fibrillation/mid-regional-pro-atrial-natriuretic-peptide-mr-proanp.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-10-08 · Page generated from atrial-fibrillation.json · Browse: Atrial Fibrillation atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.